CUE vs. AFMD, SLS, BTAI, VTVT, ASMB, ACRS, RLYB, JAGX, HOOK, and TPST
Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Affimed (AFMD), SELLAS Life Sciences Group (SLS), BioXcel Therapeutics (BTAI), vTv Therapeutics (VTVT), Assembly Biosciences (ASMB), Aclaris Therapeutics (ACRS), Rallybio (RLYB), Jaguar Health (JAGX), Hookipa Pharma (HOOK), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical preparations" industry.
Affimed (NASDAQ:AFMD) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability.
In the previous week, Affimed had 3 more articles in the media than Cue Biopharma. MarketBeat recorded 5 mentions for Affimed and 2 mentions for Cue Biopharma. Affimed's average media sentiment score of 1.82 beat Cue Biopharma's score of 0.70 indicating that Cue Biopharma is being referred to more favorably in the news media.
Affimed presently has a consensus target price of $45.00, suggesting a potential upside of 770.41%. Cue Biopharma has a consensus target price of $8.00, suggesting a potential upside of 332.43%. Given Cue Biopharma's higher probable upside, equities analysts clearly believe Affimed is more favorable than Cue Biopharma.
Affimed has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.
Cue Biopharma has a net margin of -711.84% compared to Cue Biopharma's net margin of -1,280.27%. Cue Biopharma's return on equity of -118.17% beat Affimed's return on equity.
30.8% of Affimed shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 3.8% of Affimed shares are owned by insiders. Comparatively, 7.5% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Cue Biopharma has lower revenue, but higher earnings than Affimed. Cue Biopharma is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
Affimed received 287 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
Summary
Affimed beats Cue Biopharma on 9 of the 17 factors compared between the two stocks.
Get Cue Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Biopharma Competitors List
Related Companies and Tools
